Contact Information: Contact: Robert P. Walker Sr. Vice President (972)639-6941
Noted Harvard School of Dental Medicine Lecturer and Periodontist Dr. Herb Bader Joins OralDNA Labs in Scientific Advisory Role
| Source: OralDNA Labs
NASHVILLE, TN--(Marketwire - January 12, 2009) - OralDNA Labs, Inc. (www.OralDNA.com), a
specialty diagnostics company focused on bringing advanced laboratory
testing to the dental community, today announced its appointment of Dr.
Herb Bader, DDS, FACD, FICD as a scientific advisor. Dr. Bader is a noted
lecturer at the Harvard School of Dental Medicine, where he received his
post-doctoral training as a research fellow in periodontology. He is a
frequent lecturer nationwide and author and thought leader in
periodontology and related areas including the immunology of inflammatory
changes, management of periodontal inflammation, and adjunctive oral cancer
screening.
In his new capacity with OralDNA, Dr. Bader will assist the OralDNA
educational outreach team led by Chairman and Chief Dental Officer Dr.
Thomas Nabors. This team's primary focus is to provide education on the
diagnosis and treatment of periodontal disease. Dr. Bader also will assist
OralDNA in its current development of an oral HPV test for use in risk
assessment for oral cancer, as well as assisting in identifying and
developing additional diagnostic tests for use in the dental setting.
"Having diagnostic tools for the effective diagnosis and subsequent
treatment of periodontal disease is long overdue within the dental
industry," said Dr. Bader. "Oral health is extremely important for the
health of the body. Periodontal disease is an infectious disease and should
be identified and treated in the same manner as we identify and treat any
infection within the body."
Dr. Bader is a Fellow of the American and International Colleges of
Dentistry, has served as a diplomate of the Academy of Osseointegration,
and is a frequent contributor to dental literature. He has been included
multiple times on the Dentistry Today annual list of top 100 clinical
educators and lectures throughout North America in the areas of
periodontics in the general practice.
"We are excited to have someone of Dr. Bader's stature join our efforts to
educate the dental community about the benefits of diagnostic testing,"
said Dr. Nabors. "Dr. Bader has long sought to increase understanding and
treatment of periodontal disease, as well as the relationship between oral
disease and systemic health of the entire body. We look forward to having
him assist OralDNA with its educational outreach and its expanding test
menu."
About OralDNA Labs, Inc. (www.OralDNA.com):
OralDNA Labs, Inc. is a specialty diagnostics company created to advance
clinical testing in the dental community. Our goal is to help the dental
profession achieve better clinical outcomes by providing reliable,
definitive and cost effective clinical tests that drive the detection and
prognosis of disease at an earlier, more treatable stage, with an initial
focus on periodontal disease.
Periodontal disease is a bacterial infection that causes an inflammatory
response. Periodontal disease is present in an estimated three quarters of
the adult population in the United States, with 30-35% of this population
having a genetic trait which predisposes these individuals to more serious
forms of the disease. If patients are not properly diagnosed and treated
at early stages, periodontal disease can lead to bone loss, tooth loss and
implant failure. Research now suggests an increased risk to a number of
systemic diseases when chronic periodontal infections are left untreated.
OralDNA offers two DNA-PCR tests for periodontal disease diagnosis and
genetic susceptibility. MyPerioPath(SM) detects the presence and quantity
of specific bacteria associated with periodontal disease. MyPerioID(SM)
PST®, licensed through a marketing, sales and distribution agreement with
Interleukin Genetics, provides a means of assessing an individual's genetic
risk for periodontal disease.
The company is also developing an oral HPV test for use in assessing risks
associated with oral cancer. Thereafter, OralDNA intends to develop a
broader menu of clinical laboratory tests for use in oral medicine.